FDA-cleared AI for heart disease: what OpenEvidence brings to the bedside
OpenEvidence, the clinical decision-support platform used by an estimated 700,000 physicians in the United States, has announced an FDA-cleared artificial-intelligence module designed to detect heart disease in early screening. The module will be available to clinicians through the platform, STAT News reported on Tuesday.
The integration of AI into clinical decision-support tools is not new. However, FDA clearance (under the 510(k) pathway) indicates that an AI module has been evaluated as a clinical device and validated for a specific use case within a physician's workflow. STAT reported that OpenEvidence's module analyzes twelve-lead ECG data to flag early signs of conditions such as arrhythmias and cardiomyopathy.
The clinical decision-support market has expanded rapidly over the last five years. Platforms such as UpToDate, DynaMed and OpenEvidence have become reference tools that help physicians support treatment decisions with research evidence. OpenEvidence was launched in 2022 by founder and CEO Daniel Nadler and received funding at a $4 billion valuation earlier this year.
Heart disease is the leading cause of death in the United States, accounting for roughly 700,000 deaths in 2023 according to CDC data. Early detection, particularly in cardiomyopathies and inherited arrhythmias, can materially change the outcome of intervention. OpenEvidence says the module is designed mainly to help primary-care physicians catch early signs.
The FDA's guidance for AI/ML-based medical devices emphasizes the importance of clinical validation and the pre-specification of changes to models. STAT noted that OpenEvidence has not yet detailed which datasets the module was trained on; the company plans to publish a clinical validation paper in the coming months.
Cardiologist Dr Eric Topol of Scripps Research told STAT that "AI re-reading of ECGs has become one of the most exciting areas of clinical cardiology over the past few years." Topol added that similar work at centers including the Mayo Clinic and Apollo Hospitals in India has reached lifesaving potential.
A significant question raised by AI use in decision support is the management of false positives and false negatives. How a clinician orders additional tests or makes referrals when the module flags a specific risk may require reorganizing clinical workflows. OpenEvidence said its product leadership is preparing structured recommendations through clinical advisory committees.
On the payment side, although insurers have begun reimbursing AI-based screening tools, a stable coding system has not yet settled. The Medicare proposed fee schedule for fiscal 2026 suggested a reimbursement pathway for AI-assisted echocardiography interpretation, which could accelerate adoption by vendors such as OpenEvidence.
Physician acceptance is a critical question. According to a survey published by the American Heart Association last year, 62 percent of cardiologists found AI-assisted diagnostic tools "useful or very useful" in clinical practice, while 28 percent reported being concerned about liability sharing. OpenEvidence said it is addressing that through its clinical leadership board.
STAT reported that OpenEvidence plans to start the first pilot with four regional health systems in September. The company has not given a precise estimate of when the module will generate full revenue; executives anticipate a broader rollout in early 2027.
Read next
Two sides of the same fat family: one fuels type 2 diabetes while the other fights it
A new study finds a striking difference between two structural variations of a saturated fatty acid that affect type 2 diabetes risk in opposite directions. The findings, reported by Science Daily, highlight an important nuance in nutrition science.
Why do we get better with age? Yale study finds nearly half of older adults improve over time
A long-term study from Yale University finds that nearly half of older adults show improvement in physical or psychological health over time. The findings challenge framings that view aging only as a decline, and align with a shift in aging research.
IVF add-on treatments: a new analysis finds most have no effect on success
A new analysis finds that the large majority of add-on treatments often sold during IVF cycles in the United Kingdom have no measurable benefit on success rates, and the evidence base for most remains insufficient. Reported by the Guardian, the work questions the real value of practices that often cost patients several thousand pounds in extra charges.
Five-minute walk at work: what new research says about feeling happier on the job
A walk of just five minutes during the workday can produce a measurable lift in mood. According to new research described by BBC Health, simple intermittent movement habits lower stress indicators.
Eli Lilly's experimental obesity drug retatrutide given to a single patient: how the unusual access is being explained
Eli Lilly has provided its experimental obesity drug retatrutide, which has not yet completed Phase 3 trials, to a single 79-year-old patient through a "compassionate use" program. The case, detailed by STAT News, raises significant questions about how access to investigational drugs is granted before FDA approval.
